Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Rank

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Journal of Clinical Medicine|August 7, 2021
One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term SymptomsAndreas Rank, Athanasia Tzortzini, Elisabeth Kling, et al.
Transplantation and Cellular Therapy|May 9, 2021
Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAndreas Rank, Christophe Peczynski, Myriam Labopin, et al.
Frontiers in Cardiovascular Medicine|December 31, 2021
Histopathology-Based Deep-Learning Predicts Atherosclerotic Lesions in Intravascular ImagingOlle Holmberg, Tobias Lenz, Valentin Koch, et al.
International Journal of Molecular Sciences|December 23, 2023
Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte CultureMarianne Unterfrauner, Hazal Aslan Rejeski, Anne Hartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose ChemotherapyPaul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Oncology Reports|June 20, 2025
Role of extracellular vesicles as promotors for activation of leukemia‑derived dendritic cell‑mediated antileukemic immune response against AML‑blastsLin Li, André Görgens, Veronika Mussack, et al.
International Journal of Molecular Sciences|January 8, 2025
In Vivo Induction of Leukemia-Specific Adaptive and Innate Immune Cells by Treatment of AML-Diseased Rats and Therapy-Refractory AML Patients with Blast Modulating Response ModifiersMichael Atzler, Tobias Baudrexler, Daniel Christoph Amberger, et al.
JAMA Oncology|February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin LymphomaJustin Ferdinandus, Horst Müller, Janina Jablonski, et al.
International Journal of Molecular Sciences|February 26, 2025
Leukemia-Derived Dendritic Cells Induce Anti-Leukemic Effects Ex Vivo in AML Independently of Patients' Clinical and Biological FeaturesLara Kristina Klauer, Hazal Aslan Rejeski, Selda Ugur, et al.
Clinical Immunology (Orlando, Fla.)|July 31, 2022
Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemiaCaroline Plett, Lara Kristina Klauer, Daniel Christoph Amberger, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Journal of Clinical Medicine|August 7, 2021
One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term SymptomsAndreas Rank, Athanasia Tzortzini, Elisabeth Kling, et al.
Transplantation and Cellular Therapy|May 9, 2021
Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAndreas Rank, Christophe Peczynski, Myriam Labopin, et al.
Frontiers in Cardiovascular Medicine|December 31, 2021
Histopathology-Based Deep-Learning Predicts Atherosclerotic Lesions in Intravascular ImagingOlle Holmberg, Tobias Lenz, Valentin Koch, et al.
International Journal of Molecular Sciences|December 23, 2023
Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte CultureMarianne Unterfrauner, Hazal Aslan Rejeski, Anne Hartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose ChemotherapyPaul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Oncology Reports|June 20, 2025
Role of extracellular vesicles as promotors for activation of leukemia‑derived dendritic cell‑mediated antileukemic immune response against AML‑blastsLin Li, André Görgens, Veronika Mussack, et al.
International Journal of Molecular Sciences|January 8, 2025
In Vivo Induction of Leukemia-Specific Adaptive and Innate Immune Cells by Treatment of AML-Diseased Rats and Therapy-Refractory AML Patients with Blast Modulating Response ModifiersMichael Atzler, Tobias Baudrexler, Daniel Christoph Amberger, et al.
JAMA Oncology|February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin LymphomaJustin Ferdinandus, Horst Müller, Janina Jablonski, et al.
International Journal of Molecular Sciences|February 26, 2025
Leukemia-Derived Dendritic Cells Induce Anti-Leukemic Effects Ex Vivo in AML Independently of Patients' Clinical and Biological FeaturesLara Kristina Klauer, Hazal Aslan Rejeski, Selda Ugur, et al.
Clinical Immunology (Orlando, Fla.)|July 31, 2022
Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemiaCaroline Plett, Lara Kristina Klauer, Daniel Christoph Amberger, et al.
Pageof 8